TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01724814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
Study: NCT04859556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon 25Gauge, 10,000 cuts per minute Ultravit cutter
Description: a proprietary Vitrector from Alcon for the use on the Constellation system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alcon 25Gauge, 5,000 cuts per minute Ultravit cutter
Description: a proprietary Vitrector from Alcon for the use on the Constellation system
Study: NCT01724814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Singe dose SC administration of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Singe dose SC administration of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Singe dose SC administration of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Singe dose SC administration of Placebo
Study: NCT03329833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing will consist of weekly phone calls for two months, bi-weekly phone calls for two months, and monthly phone calls for two months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing will consist of weekly phone calls for two months, bi-weekly phone calls for two months, and monthly phone calls for two months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based application
Description: Web-based application participants will be asked to log activity at least on a daily basis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based application
Description: Web-based application participants will be asked to log activity at least on a daily basis.
Study: NCT01724814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Singe dose SC administration of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Singe dose SC administration of Placebo
Study: NCT01955265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sports mentorship programme
Description: 1.5-hour sports mentorship session once a week, 18 weeks total.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion
Description: The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
Study: NCT02468505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS
Description: time-limited behavioral counseling, online materials, training
Study: NCT03869710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Dry-Needling Therapy
Description: The needle will be insert under ultrasound guidance to elicit the myofascial response on the neck of the patients
Study: NCT03688295

Intervention type: OTHER
Group type: OTHER
Intervention: No antibiotics
Description: Patients will not receive antiobitherapy post surgery for CAA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Patients will receive antiobitherapy post surgery for CAA
Study: NCT02065245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Description: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Description: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Description: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Description: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Description: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Description: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Description: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered by peripheral intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Description: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion.
Study: NCT00103701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
Study: NCT02766478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Genistein is a natural supplement that comes from soy. Genistein will be taken orally (30 mg twice daily) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill will be taken orally for 12 weeks.
Study: NCT04699448

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional intervention.
Description: Diets designed for body weight loss, based on different macronutrient content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional intervention.
Description: Diets designed for body weight loss, based on different macronutrient content.
Study: NCT03494699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary prevention
Description: group cognitive training (every month) App-based Cognitive Training at Home (using smartphone application) physical activity/body weight/smoking \& alcohol cessation monitoring and feedback
Study: NCT01095224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd35 Env A
Description: 1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd35 Env A
Description: 1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd35 Env A
Description: 1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 Env A
Description: 1 x 10\^10 PU administered as 1 mL IM in deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 Env A
Description: 1 x 10\^10 PU administered as 1 mL IM in deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 Env A
Description: 1 x 10\^10 PU administered as 1 mL IM in deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 Env B
Description: 1 x 10\^10 PU administered as 1 mL IM in deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 Env B
Description: 1 x 10\^10 PU administered as 1 mL IM in deltoid
Study: NCT02941146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting System will be used to perform the treatments with the CoolAdvantage family of applicators.
Study: NCT05732948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous T cells & cyclophosphamide
Description: This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of PD-1(programmed death 1)silent PSMA(prostate-specific membrane antigen)/PSCA(prostate stem cell antigen)targeted CAR-T administered one day after pretreatment with cyclophosphamide.
Study: NCT01972087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone simulation training
Description: The intervention consists of four 20-minute telephone simulation training sessions over a 4 month period (one session each month). Each 20-minute training session will include 3 simulated 9-1-1 calls, performed by a standardized caller (trained actor) and feedback will be provided right away by a trained observer who takes notes during the simulation calls and discusses the teaching points after the session. In total, the 9-1-1 dispatchers will receive 12 different simulated calls.
Study: NCT03766919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant of the INVICTA lead
Description: The implant or the attempt to implant an INVICTA lead
Study: NCT01890967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Administered orally
Study: NCT01785615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80mg
Study: NCT04520061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Insurance Navigation Program
Description: The program will be delivered via videoconferencing by a navigator over a 2-month period and will consist of 4 sessions. The navigation intervention sessions will be as follows: Session 1- Learning About Survivorship Healthcare Needs; Session 2- Learning About Your Plan in Relation to Policy; Session 3- Navigating One's Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs.
Study: NCT03782662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole capsules
Study: NCT01890967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Administered orally
Study: NCT03782662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam oromucosal solution
Study: NCT01890967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin
Description: Administered orally
Study: NCT03782662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oromucosal solution
Study: NCT01890967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally
Study: NCT03782662

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for RV521
Description: Placebo for RV521 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV521
Description: RV521 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV521
Description: RV521 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV521
Description: RV521 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV521
Description: RV521 capsules
Study: NCT03843125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study: NCT04460443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: Sofosbuvir once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir ledipsavir
Description: Sofosbuvir ledipsavir once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daklatasuvir tablets
Study: NCT00375856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DePuy P.F.C.® Sigma Rotating Platform Knee
Description: no details
Study: NCT03453632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinic toxin
Description: Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of botulinic toxin (200 UI) on right or left foot

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of physiological serum (200 UI) on right or left foot
Study: NCT04737590

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioactive glass
Description: Comparison of bioactive glass to allogenic bone in pediatric bone cysts
Study: NCT01081574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: 10 mg/qd/ 7 days.Oral dispersible tablets
Study: NCT04154163

Intervention type: DIAGNOSTIC_TEST
Intervention: Dried blood Spot (DBS)
Description: Dried Blood Spot filter paper and sponges

Intervention type: DIAGNOSTIC_TEST
Intervention: Dried blood Spot (DBS)
Description: Dried Blood Spot filter paper and sponges

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sampling
Description: Venous blood
Study: NCT01005979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Rituximab, and Cyclophosphamide
Description: COHORT 1: Cyclophosphamide 250 mg/m2 day 1, 2 and 3, Rituximab 500 mg/m2 i.v. day 1, Lenalidomide 2.5 mg/day starting day 8-28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 2: Cyclophosphamide 250mg/m2 day 1, 2 and 3. Rituximab 500 mg.m2 i.v. daY Lenalidomide 5 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 3: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 10 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 4: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 15 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~Patients will receive a total of 6-8 cycles.
Study: NCT00054717

Intervention type: DRUG
Group type: OTHER
Intervention: Tipranavir
Study: NCT04391751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal tunnel release and basal joint arthroplasty through single incision
Description: Group I: experimental - single incision The surgical technique chosen for thumb basal join was trapeziectomy with ligamentous reconstruction and tendon interposition (LRTI), using flexor carpi radialis (FCR). Through a dorsal approach over trapeziometacarpal joint, the entire trapezium was excised. Volar traction of FCR allowed us to longitudinally incise the deep leaflet of FCR tendon until flexor pollicis longus (FPL) tendon was clearly visualized. Then, ulnar half of FCR tendon was harvested proximally through a second transverse incision in middle third of the forearm and split all the way to its insertion on the index metacarpal. A hole was placed in the base of the first metacarpal and FCR tendon was routed through the bone canal and then fixed with non-reabsorbable sutures. Finally, the tendon remanent was rolled up and placed into the trapezial void to act as a spacer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel release and basal joint arthroplasty through double incision
Description: Group II: active comparator - double incision Trapezial excision and ligament reconstruction were performed in the same way as in group I, except that FCR deep leaflet was not incised. After radial incision wound closure, carpal tunnel release was performed through a second separate longitudinal palmar incision.
Study: NCT00054717

Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir(r)

Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir(r)

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator Protease Inhibitor (CPI)
Study: NCT00958425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Normal saline, 0.9 mL, intradermal over 2 cm area, once
Study: NCT03390686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg IV every 3 weeks on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD204
Description: 15 mg/kg IV every 3 weeks on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
Study: NCT01616563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription and Fitness Program
Description: Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
Study: NCT02424344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium/Formoterol
Description: Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
Study: NCT03115775

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated linoleic acid
Description: Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Intervention will last up to 8 weeks. Subjects will receive vitamin D3 (2000 IU) daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated linoleic acid and Vitamin D
Description: Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) and vitamin D3 (2000 IU) daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil (placebo)
Description: Intervention will last up to 8 weeks. Subjects will receive corn oil (4000 mg) daily.
Study: NCT02201030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP606
Description: A single intramuscular injection into the thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13
Description: A single intramuscular injection into the thigh
Study: NCT00412516

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Live attenuated SA 14-14-2 vaccine
Description: Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated SA 14-14-2 vaccine
Description: Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Live attenuated SA 14-14-2 vaccine
Description: Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)